Fibroadenoma
A fibroadenoma is a benign solid lump made of glandular and fibrous breast tissue, and the most common breast mass in young women. It typically feels smooth, firm, and rubbery, and is strikingly mobile—many women describe a lump that slips away under the fingers when pressed. Fibroadenomas are not cancer, do not become cancer, and in the typical case do not meaningfully increase the risk of developing breast cancer later. Most are left in place once the diagnosis is confirmed, since removing them achieves nothing beyond leaving a scar. A proportion shrink or disappear on their own, and most become smaller after menopause as the hormonal stimulation that sustains them falls away.
What is it?
The breast contains lobules that produce milk, ducts that carry it, and surrounding fibrous and fatty supporting tissue. A fibroadenoma arises from a single lobule and the connective tissue immediately around it, which together overgrow to form a discrete, well-circumscribed lump. The name reflects its composition: fibrous tissue and glandular tissue combined.
It is not a true tumour in the sense of an uncontrolled clonal growth. It is better understood as a localised overgrowth of normal breast tissue elements in response to hormonal stimulation—an exaggeration of normal development rather than a disease process. This framing explains much of its behaviour.
Fibroadenomas are hormone-responsive. They contain oestrogen and progesterone receptors and respond to the same cycling that produces normal breast changes. They frequently enlarge slightly and become more tender before a period. They grow during pregnancy and breastfeeding, sometimes markedly. They typically shrink and may calcify after menopause as hormonal stimulation declines. And they rarely appear as new lesions after menopause unless a woman is taking hormone replacement therapy.
Several variants exist and are worth distinguishing.
A simple fibroadenoma is the usual form, composed of uniform tissue without additional features, and carries essentially no increase in future breast cancer risk.
A complex fibroadenoma contains additional changes identified under the microscope, including cysts, sclerosing adenosis, calcification, or apocrine change. These carry a modestly increased risk of breast cancer developing in the future—roughly double that of the general population—though the absolute risk remains low. The distinction is made by the pathologist rather than by imaging or examination, and it occasionally alters follow-up advice.
A giant fibroadenoma is one exceeding roughly five centimetres, which may distort the breast and is usually removed for that reason.
A juvenile fibroadenoma occurs in adolescents, can grow rapidly and reach a large size, and often warrants removal because of the distortion it causes rather than because of any risk.
Phyllodes tumour is the important lookalike. It arises from similar tissue and can be indistinguishable from a fibroadenoma on examination, imaging, and even on needle biopsy. The clinical clue is rapid growth, particularly in a woman over 35 or in a lesion that was previously stable. Phyllodes tumours are graded from benign through borderline to malignant, and even benign ones recur locally if not removed with a clear margin of surrounding tissue. This is the principal reason a rapidly growing lesion is excised rather than observed, and why a biopsy report suggesting a fibroadenoma may still prompt surgery if the growth pattern does not fit.
The cause is not fully established, but hormonal influence is clearly central. Fibroadenomas appear during the reproductive years, respond to hormonal cycling, grow in pregnancy, and regress after menopause. Nothing a woman does causes them, and they are not related to diet, caffeine, injury, or breast trauma—reassurances worth stating, since women frequently search for an explanation.
There is one recognised association worth knowing: ciclosporin, an immunosuppressant used after organ transplantation, is associated with the development of multiple fibroadenomas.
The typical presentation is distinctive enough to be suggestive, though never diagnostic on its own.
A woman, often in her twenties, notices a painless lump. On examination it is smooth, firm with a slightly rubbery consistency, well-defined with clear edges, and conspicuously mobile—it slides under the examining finger rather than staying put, which is the origin of the informal term breast mouse. Most measure one to three centimetres.
Some women report mild tenderness or a sense that the lump enlarges before a period.
Many fibroadenomas cause no symptoms at all and are found incidentally during imaging performed for another reason.
It is essential to state that these classical features cannot establish the diagnosis. Cancers can occasionally feel smooth and mobile, particularly some higher-grade tumours and certain subtypes that are well-circumscribed. The characteristic feel of a fibroadenoma raises the probability substantially but does not remove the need for assessment, and any new breast lump should be evaluated regardless of how reassuring it feels.
Diagnosis follows the standard triple assessment framework used for any breast mass.
Clinical examination assesses the lump and the surrounding breast.
Ultrasound is the primary imaging test and is well suited to the young women in whom fibroadenomas occur, where dense breast tissue limits mammography. The typical appearance is a well-defined oval mass, uniformly darker than surrounding tissue, wider than it is tall, with smooth or gently lobulated margins and no significant shadowing behind it. These features are characteristic but not exclusive, and some cancers can appear similarly.
Mammography is added in women over 40. A fibroadenoma appears as a well-defined mass, and longstanding lesions in older women often develop coarse calcification with a characteristic appearance commonly described as popcorn-like, which is confidently diagnostic when present.
Core needle biopsy provides the definitive answer. Whether it is required depends on circumstances. In a young woman with an entirely typical lump and classical ultrasound appearances, some centres manage without biopsy, relying on the concordance of clinical and imaging assessment with follow-up to confirm stability. In most other situations biopsy is performed, since it converts a probable diagnosis into a certain one, and the procedure is quick and done under local anaesthetic.
Short-interval follow-up imaging, typically at six months, is used where a lesion is assessed as probably benign and biopsy is not performed, on the basis that a benign lesion will remain stable while anything concerning will change.
The features that prompt a different approach are specific: rapid growth, size above roughly three centimetres or increasing on follow-up, new onset in a woman over 35 or after menopause, irregular margins or other atypical imaging features, and any associated skin or nipple change. Any of these shifts management toward biopsy or excision.
Important to Know
The central message is reassuring and worth stating plainly: a fibroadenoma confirmed by proper assessment is benign, does not turn into cancer, and in the typical case does not meaningfully raise the risk of developing breast cancer in the future. Care is typically managed by breast clinics and primary care.
Leaving it alone is the standard approach, and this is sometimes surprising to women who expect a lump to be removed. Surgery provides no health benefit for a confirmed simple fibroadenoma. It involves an anaesthetic, leaves a scar, and can produce a contour change in the breast, which in a young woman matters. Observation is not a lesser option or a compromise—it is the appropriate management.
A proportion of fibroadenomas resolve on their own. Studies following untreated lesions have found that a meaningful share shrink or disappear over several years, particularly smaller ones in younger women, while most of the remainder stay the same size. Progressive growth is the minority pattern.
Surgical removal is appropriate in defined circumstances: where the lesion is large or growing, where it causes pain or distorts the breast, where the diagnosis remains uncertain despite assessment, and where a woman has been fully informed that removal is not medically necessary but prefers it anyway. That last category is legitimate—living with a known lump in the breast causes genuine anxiety for some women, and choosing removal for that reason is a reasonable decision rather than an overreaction.
Minimally invasive alternatives are available at some centres and are worth asking about where removal is wanted. Vacuum-assisted excision removes the lesion in fragments through a small incision under local anaesthetic, with a considerably smaller scar than open surgery, and is suitable for lesions up to a certain size. Cryoablation freezes the lesion in place, leaving it to be absorbed over subsequent months, and avoids an incision entirely. Both have the limitation that no single intact specimen is produced for examination, and neither is universally available.
A rapidly growing lesion is managed differently, and the reason is phyllodes tumour. Because phyllodes can be indistinguishable from fibroadenoma on biopsy, and because even benign phyllodes recurs if not removed with a margin, rapid growth prompts excision rather than observation. A woman told that her apparently benign lump needs removing because it has grown may find this confusing, and this is the explanation.
Follow-up arrangements vary. Where a fibroadenoma is confirmed by biopsy and left in place, many centres provide no routine follow-up, advising instead that any change should be reported. Others arrange one or two interval scans to confirm stability. Either approach is reasonable, and the practical point is that a woman should know what to look for rather than relying on a schedule.
A complex fibroadenoma, identified by the pathologist, carries a modestly increased future risk and may prompt a discussion about longer-term breast awareness or earlier screening, though it does not generally warrant intensive surveillance given how low the absolute risk remains.
Fibroadenomas do not interfere with breastfeeding, do not affect fertility, and do not prevent normal breast function. They may enlarge during pregnancy and breastfeeding and typically settle afterwards. A new or enlarging lump during pregnancy should still be assessed rather than assumed to be a known fibroadenoma behaving predictably, since pregnancy-associated breast cancer is frequently diagnosed late for exactly this reason.
Hormonal contraception does not need to be avoided because of a fibroadenoma, and there is no established reason to change contraception on this basis.
Breast awareness remains important. A woman with a known fibroadenoma should continue to notice changes in her breasts and report anything new, rather than attributing every finding to the known lump. Having one benign lesion does not protect against developing something else, and a new lump in a different location warrants assessment on its own merits.
Screening attendance is unaffected. Women with fibroadenomas attend routine screening at the usual intervals and are not candidates for additional surveillance on this basis alone.
Care is managed by breast services using triple assessment, with imaging, clinical, and pathology findings interpreted together and discordance between them prompting further investigation.
Patient education plays an important role. Understanding that a fibroadenoma is an overgrowth of normal tissue rather than a tumour, that it will not become cancer, that leaving it alone is appropriate rather than negligent, that some disappear on their own, that rapid growth is the one feature that changes management, and that any new or different change still warrants assessment all contribute to appropriate care and considerably less anxiety.
Red flag symptoms include a lump that is growing, particularly rapidly; a previously stable lump that has changed in size, shape, or consistency; a lump that has become hard, irregular, or fixed rather than mobile; a new lump appearing after the age of 35 or after menopause; dimpling, puckering, or tethering of the overlying skin; new nipple inversion or change in direction; spontaneous discharge from a single duct, particularly if bloodstained; a lump in the armpit; and any new breast change in a woman with a strong family history or known high-risk gene alteration. These warrant prompt medical evaluation regardless of a previous diagnosis of fibroadenoma.